OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth
Treatment of glioblastoma (GBM) remains a challenge using conventional chemotherapy, such as temozolomide (TMZ), and is often ineffective as a result of drug resistance. We have assessed a novel nitrone-based agent, OKN-007, and found it to be effective in decreasing tumor volumes and increasing sur...
Main Authors: | Rheal A. Towner, Nataliya Smith, Debra Saunders, Chase A. Brown, Xue Cai, Jadith Ziegler, Samantha Mallory, Mikhail G. Dozmorov, Patricia Coutinho De Souza, Graham Wiley, Kyeongsoon Kim, Shinwook Kang, Doo-Sik Kong, Young-Tae Kim, Kar-Ming Fung, Jonathan D. Wren, James Battiste |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-02-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523318303954 |
Similar Items
-
TMZ-BioShuttle – a reformulated Temozolomide
by: Waldemar Waldeck, Manfred Wiessler, Volker Ehemann, Ruediger Pipkorn, Herbert Spring, Juergen Debus, Bernd Didinger, Gabriele Mueller, Joerg Langowski, Klaus Braun
Published: (2008-01-01) -
Inhibition of YB-1 alone or in combination with TMZ may improve GBM treatment
by: Gao, Yuanyuan
Published: (2009) -
Inhibition of YB-1 alone or in combination with TMZ may improve GBM treatment
by: Gao, Yuanyuan
Published: (2009) -
Inhibition of YB-1 alone or in combination with TMZ may improve GBM treatment
by: Gao, Yuanyuan
Published: (2009) -
Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
by: Luca Napoleoni, et al.
Published: (2019-01-01)